Inhibiting metalloproteases with PD 166793 in heart failure: Impact on cardiac remodeling and beyond

Nina Kaludercic, Merry L. Lindsey, Barbara Tavazzi, Giuseppe Lazzarino, Nazareno Paolocci

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


Metalloproteinases (MMPs, also called matrixins) are extracellular proteolytic enzymes involved in the degradation of both matrix and nonmatrix proteins. Currently, 25 MMPs have been identified in humans, and the overexpression of one or more MMPs has been implicated in several pathologies, spanning from cancer to rheumathoid arthritis to cardiovascular disease. While research over the past 20 years has focused on understanding MMP biology and selectively inhibiting MMP activity, key issues that remain to be addressed include MMP roles in the context of normal versus pathological conditions and whether globally inhibiting MMPs improves or deteriorates overall organ function. In terms of cardiovascular disease, increased MMP expression has been demonstrated in the setting of myocardial ischemia, reperfusion injury, and during the progression to congestive heart failure. MMPs are also major contributors to the progression of atherosclerotic lesions. In this review, we focus on cardiovascular effects produced by PD 166793, a wide-broad spectrum MMP inhibitor, originally developed by Parke-Davis (now Pfizer). We will briefly review its structure, mechanism of action, and inhibitory capacity. Finally, we will illustrate the cardiac contexts, both in vivo and in vitro, in which PD166793 administration has proven beneficial.

Original languageEnglish (US)
Pages (from-to)24-37
Number of pages14
JournalCardiovascular Therapeutics
Issue number1
StatePublished - Mar 2008
Externally publishedYes


  • AMP deaminase
  • Cardiac energetics
  • Heart failure
  • Metalloproteinases
  • Myocardial fibrosis
  • PD166793
  • Ventricular remodeling

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Inhibiting metalloproteases with PD 166793 in heart failure: Impact on cardiac remodeling and beyond'. Together they form a unique fingerprint.

Cite this